Last reviewed · How we verify
Placebo to match solifenacin succinate
Placebo to match solifenacin succinate is a Small molecule drug developed by Astellas Pharma Europe B.V.. It is currently in Phase 3 development for Placebo control for solifenacin succinate trials in overactive bladder.
This is a placebo formulation designed to match the appearance and administration of solifenacin succinate for blinded clinical trial purposes.
This is a placebo formulation designed to match the appearance and administration of solifenacin succinate for blinded clinical trial purposes. Used for Placebo control for solifenacin succinate trials in overactive bladder.
At a glance
| Generic name | Placebo to match solifenacin succinate |
|---|---|
| Sponsor | Astellas Pharma Europe B.V. |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 3 |
Mechanism of action
Placebos are inert substances used in controlled trials to provide a comparison arm against active drug. This particular placebo is manufactured to be indistinguishable from solifenacin succinate (an anticholinergic agent used for overactive bladder) in terms of appearance, taste, and packaging, enabling double-blind study design while the actual therapeutic effect comes from solifenacin's muscarinic M3 receptor antagonism.
Approved indications
- Placebo control for solifenacin succinate trials in overactive bladder
Common side effects
Key clinical trials
- Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder. (PHASE4)
- A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy (PHASE4)
- This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder (PHASE3)
- A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (PHASE3)
- A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug (PHASE3)
- A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (PHASE3)
- A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder (PHASE2)
- A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to match solifenacin succinate CI brief — competitive landscape report
- Placebo to match solifenacin succinate updates RSS · CI watch RSS
- Astellas Pharma Europe B.V. portfolio CI
Frequently asked questions about Placebo to match solifenacin succinate
What is Placebo to match solifenacin succinate?
How does Placebo to match solifenacin succinate work?
What is Placebo to match solifenacin succinate used for?
Who makes Placebo to match solifenacin succinate?
What development phase is Placebo to match solifenacin succinate in?
Related
- Manufacturer: Astellas Pharma Europe B.V. — full pipeline
- Therapeutic area: All drugs in Urology
- Indication: Drugs for Placebo control for solifenacin succinate trials in overactive bladder
- Compare: Placebo to match solifenacin succinate vs similar drugs
- Pricing: Placebo to match solifenacin succinate cost, discount & access